| Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis J Golay, L Zaffaroni, T Vaccari, M Lazzari, GM Borleri, S Bernasconi, ... Blood, The Journal of the American Society of Hematology 95 (12), 3900-3908, 2000 | 803 | 2000 |
| Complement activation determines the therapeutic activity of rituximab in vivo N Di Gaetano, E Cittera, R Nota, A Vecchi, V Grieco, E Scanziani, M Botto, ... The Journal of Immunology 171 (3), 1581-1587, 2003 | 739 | 2003 |
| PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans G Peri, M Introna, D Corradi, G Iacuitti, S Signorini, F Avanzini, F Pizzetti, ... Circulation 102 (6), 636-641, 2000 | 582 | 2000 |
| Cytokine regulation of endothelial cell function: from molecular level to the bedside A Mantovani, F Bussolino, M Introna Immunology today 18 (5), 231-235, 1997 | 565 | 1997 |
| CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 J Golay, M Lazzari, V Facchinetti, S Bernasconi, G Borleri, T Barbui, ... Blood, The Journal of the American Society of Hematology 98 (12), 3383-3389, 2001 | 562 | 2001 |
| Multimer formation and ligand recognition by the long pentraxin PTX3: similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component B Bottazzi, V Vouret-Craviari, A Bastone, L De Gioia, C Matteucci, G Peri, ... Journal of Biological Chemistry 272 (52), 32817-32823, 1997 | 524 | 1997 |
| Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program M Chieppa, G Bianchi, A Doni, A Del Prete, M Sironi, G Laskarin, P Monti, ... The Journal of Immunology 171 (9), 4552-4560, 2003 | 502 | 2003 |
| Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice M Morigi, M Introna, B Imberti, D Corna, M Abbate, C Rota, D Rottoli, ... Stem cells 26 (8), 2075-2082, 2008 | 476 | 2008 |
| Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells S Tomasoni, L Longaretti, C Rota, M Morigi, S Conti, E Gotti, C Capelli, ... Stem cells and development 22 (5), 772-780, 2013 | 383 | 2013 |
| Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility N Perico, F Casiraghi, M Introna, E Gotti, M Todeschini, RA Cavinato, ... Clinical Journal of the American Society of Nephrology 6 (2), 412-422, 2011 | 372 | 2011 |
| The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity F Tedesco, M Pausa, E Nardon, M Introna, A Mantovani, A Dobrina The Journal of experimental medicine 185 (9), 1619-1628, 1997 | 364 | 1997 |
| Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes VV Alles, B Bottazzi, G Peri, J Golay, M Introna, A Mantovani | 360 | 1994 |
| Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin F Breviario, L Caveda, M Corada, I Martin-Padura, P Navarro, J Golay, ... Arteriosclerosis, thrombosis, and vascular biology 15 (8), 1229-1239, 1995 | 351 | 1995 |
| Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity A Pievani, G Borleri, D Pende, L Moretta, A Rambaldi, J Golay, M Introna Blood, The Journal of the American Society of Hematology 118 (12), 3301-3310, 2011 | 325 | 2011 |
| M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro M Leidi, E Gotti, L Bologna, E Miranda, M Rimoldi, A Sica, M Roncalli, ... The Journal of Immunology 182 (7), 4415-4422, 2009 | 325 | 2009 |
| Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites M Introna, VV Alles, M Castellano, G Picardi, L De Gioia, B Bottazzai, ... | 301 | 1996 |
| Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab J Golay, F Da Roit, L Bologna, C Ferrara, JH Leusen, A Rambaldi, C Klein, ... Blood, The Journal of the American Society of Hematology 122 (20), 3482-3491, 2013 | 286 | 2013 |
| Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone N Di Gaetano, Y Xiao, E Erba, R Bassan, A Rambaldi, J Golay, M Introna British journal of haematology 114 (4), 800-809, 2001 | 283 | 2001 |
| Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study M Introna, G Borleri, E Conti, M Franceschetti, AM Barbui, R Broady, ... haematologica 92 (7), 952-959, 2007 | 274 | 2007 |
| Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients M Introna, G Lucchini, E Dander, S Galimberti, A Rovelli, A Balduzzi, ... Biology of blood and marrow transplantation 20 (3), 375-381, 2014 | 272 | 2014 |
